Targets › IL18
4 programs from 4 companies in 5 trials: 4 Phase 1, 1 Phase 2; Oncology, Immunology; next expected readout Oct 2027.
Pro-inflammatory cytokine primarily involved in epithelial barrier repair, polarized T-helper 1 (Th1) cell and natural killer (NK) cell immune responses. Upon binding to IL18R1 and IL18RAP, forms a signaling ternary complex which activates NF-kappa-B, triggering synthesis of inflammatory mediators. (UniProt, Q14116)
Open in Phaseline: the race on IL18, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Apollo Therapeutics | Camoteskimab Interleukin-18 cross-linking agent | IL18 | Phase 2 | Atopic Dermatitis | Oct 2027 |
| Memorial Sloan Kettering Cancer Center | 19-28z/IL-18 CAR T cells CAR-T cell therapy targeting CD19 with IL-18 co-expression | CD19, IL18 | Phase 1 | Philadelphia-Negative ALL | Feb 2028 |
| GSK | Aletekitug (GSK1070806) Anti-IL-18 monoclonal antibody | IL18 | Phase 1 | Colitis, Ulcerative | Mar 2028 |
| Simcha IL-18 | ST-067 Engineered variant of human interleukin-18 | IL18 | Phase 1 | Cancer | – |
Colitis, Ulcerative (2) Cancer (1) Atopic Dermatitis (1) Philadelphia-Negative ALL (1)
antibody (2), mixed (1), other (1)
Simcha IL-18 (1) Apollo Therapeutics (1) Memorial Sloan Kettering Cancer Center (1) GSK (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.